With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumours.
Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.
Researchers have developed a technique that allowed them to determine at diagnosis whether children with acute lymphoblastic leukaemia would relapse following treatment.
23andMe has received the first-ever FDA authorisation for a direct-to-consumer genetic test for cancer risk for its BRCA1 and BRCA2 report.
Scientists created an odd couple: a modified version of an immune-signalling protein and a coordinately modified receptor for this protein. The two bind only to each other, easing an advanced anti-cancer therapy’s side effects.
Researchers report that they have developed a method for identifying splicing-based biomarkers for the most common form of liver cancer. They believe the method will be useful in other cancer types as well.
There are wide differences in BRCA testing protocols at labs around the world. A new article surveyed 86 laboratories about their BRCA testing practices and found that all the labs differed widely in their approach.
Light-activated cancer drugs that don’t cause the toxic side effects of current chemotherapy treatments are closer to becoming a reality, a new study suggests.